Aquinox to price initial public stock sale between $10.00 and $12.00

Jefferies and Cowen will be the joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Feb. 28 - Aquinox Pharmaceuticals, Inc. will sell 3.7 million common shares in its initial public offering with a 30-day greenshoe, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced Jan. 28.

The shares will be sold at a price expected to fall between $10.00 and $12.00 per share.

Jefferies and Cowen and Co. are the joint bookrunning managers. Canaccord Genuity is the co-manager.

Proceeds will be used for clinical trials, toxicology studies, large batch manufacturing and process development, to advance products through preclinical development and for working capital, capital expenditures and other general corporate purposes.

The clinical-stage pharmaceutical company is based in Vancouver, B.C. It intends to list its common stock on the Nasdaq under the symbol "AQXP."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.